CN112638898B - 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 - Google Patents

杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 Download PDF

Info

Publication number
CN112638898B
CN112638898B CN201980056968.7A CN201980056968A CN112638898B CN 112638898 B CN112638898 B CN 112638898B CN 201980056968 A CN201980056968 A CN 201980056968A CN 112638898 B CN112638898 B CN 112638898B
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
independently
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201980056968.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112638898A (zh
Inventor
蒂洛·福肯
让-克里斯托夫·安德烈斯
克里斯汀·尼科尔·伯福德
克里斯托夫·马丁·德纳德
迈克尔·爱德华·格里伍德
贾琦
弗纳·亚历山大·洛夫斯特兰德
史蒂文·西格蒙德·韦索洛斯基
迈克尔·斯科特·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CN112638898A publication Critical patent/CN112638898A/zh
Application granted granted Critical
Publication of CN112638898B publication Critical patent/CN112638898B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980056968.7A 2018-08-31 2019-08-29 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 Expired - Fee Related CN112638898B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725960P 2018-08-31 2018-08-31
US62/725,960 2018-08-31
PCT/US2019/048900 WO2020047312A1 (en) 2018-08-31 2019-08-29 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Publications (2)

Publication Number Publication Date
CN112638898A CN112638898A (zh) 2021-04-09
CN112638898B true CN112638898B (zh) 2024-04-09

Family

ID=67953871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056968.7A Expired - Fee Related CN112638898B (zh) 2018-08-31 2019-08-29 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途

Country Status (7)

Country Link
US (1) US10752623B2 (enExample)
EP (1) EP3844158A1 (enExample)
JP (1) JP7383012B2 (enExample)
CN (1) CN112638898B (enExample)
CA (1) CA3104913A1 (enExample)
MA (1) MA53488A (enExample)
WO (1) WO2020047312A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201468A1 (en) 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP3551626B1 (en) 2016-12-09 2023-10-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
AU2019285184B2 (en) 2018-06-13 2023-11-16 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
AR133184A1 (es) * 2023-07-07 2025-09-03 Novartis Ag Bloqueadores de canales de sodio
WO2026133152A1 (en) * 2024-12-18 2026-06-25 Novartis Ag Sodium channel blockers

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863785A (zh) * 2003-08-08 2006-11-15 沃泰克斯药物股份有限公司 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
WO2010026365A1 (en) * 2008-09-02 2010-03-11 University Of Dundee N-myristoyl transferase inhibitors
CN101883760A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的杂芳基酰胺类
CN103119045A (zh) * 2010-08-20 2013-05-22 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
CN104024251A (zh) * 2011-10-31 2014-09-03 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
CN104718188A (zh) * 2012-05-22 2015-06-17 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
CN106255679A (zh) * 2014-02-27 2016-12-21 默克专利有限公司 用作na v通道抑制剂的杂环化合物及其用途
WO2017201468A1 (en) * 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN107690281A (zh) * 2014-10-06 2018-02-13 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2018042316A1 (en) * 2016-08-29 2018-03-08 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2018106284A1 (en) * 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN112930175A (zh) * 2018-07-27 2021-06-08 泽农医药公司 治疗癫痫的方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
ATE250932T1 (de) 1999-07-16 2003-10-15 Warner Lambert Co Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2531418A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2007039171A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2007075895A2 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
US8853250B2 (en) 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
JP5460589B2 (ja) * 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
EP2307412A2 (en) 2008-07-01 2011-04-13 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
AU2012296529A1 (en) 2011-08-17 2014-02-20 Amgen Inc. Heteroaryl sodium channel inhibitors
AU2012328561A1 (en) 2011-10-28 2014-04-17 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US9376429B2 (en) 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
JP2015535251A (ja) 2012-10-26 2015-12-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有するベンゾオキサゾリノン化合物
AU2013334664A1 (en) 2012-10-26 2015-05-07 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
WO2015035278A1 (en) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
CA2934473C (en) 2013-12-23 2019-08-20 Purdue Pharma L.P. Indazoles and use thereof
KR102412146B1 (ko) * 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
BR112018012408A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica?
US10668067B2 (en) * 2016-07-20 2020-06-02 Amgen Inc. Pyridine sulfonamides
US10968210B2 (en) 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863785A (zh) * 2003-08-08 2006-11-15 沃泰克斯药物股份有限公司 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
CN101883760A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的杂芳基酰胺类
WO2010026365A1 (en) * 2008-09-02 2010-03-11 University Of Dundee N-myristoyl transferase inhibitors
CN103119045A (zh) * 2010-08-20 2013-05-22 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
CN104024251A (zh) * 2011-10-31 2014-09-03 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
CN104718188A (zh) * 2012-05-22 2015-06-17 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
CN106255679A (zh) * 2014-02-27 2016-12-21 默克专利有限公司 用作na v通道抑制剂的杂环化合物及其用途
CN107690281A (zh) * 2014-10-06 2018-02-13 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2017201468A1 (en) * 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2018042316A1 (en) * 2016-08-29 2018-03-08 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2018106284A1 (en) * 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN112930175A (zh) * 2018-07-27 2021-06-08 泽农医药公司 治疗癫痫的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chapter 15-Molecular Variations Based on Isosteric Replacements;Paola Ciapetti and Bruno Giethlen;The Practice of Medicinal Chemistry (THIRD EDITION);290-342 *

Also Published As

Publication number Publication date
MA53488A (fr) 2021-12-08
JP7383012B2 (ja) 2023-11-17
WO2020047312A1 (en) 2020-03-05
JP2021535137A (ja) 2021-12-16
US10752623B2 (en) 2020-08-25
US20200071313A1 (en) 2020-03-05
CN112638898A (zh) 2021-04-09
CA3104913A1 (en) 2020-03-05
EP3844158A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
US11299490B2 (en) Benzenesulfonamide compounds and their use as therapeutic agents
CN112638879B (zh) 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途
US10752623B2 (en) Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CA2853439A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
HK40049688A (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
HK40005248A (en) Benzenesulfonamide compounds and their use as therapeutic agents
HK40005248B (en) Benzenesulfonamide compounds and their use as therapeutic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240409